Sarepta Therapeutics (NASDAQ:SRPT) had its price objective reduced by Needham & Company LLC to $196.00 in a research note released on Monday morning, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other analysts have also issued reports on SRPT. Piper Jaffray Companies restated an overweight rating and issued a $168.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, June 20th. BidaskClub lowered shares of Sarepta Therapeutics from a strong-buy rating to a buy rating in a research note on Saturday, September 22nd. Cowen restated an outperform rating and issued a $178.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, June 20th. Morgan Stanley lifted their price target on shares of Sarepta Therapeutics from $91.00 to $163.00 and gave the stock an equal weight rating in a research note on Wednesday, June 20th. Finally, SunTrust Banks lifted their price target on shares of Sarepta Therapeutics to $176.00 and gave the stock a buy rating in a research note on Friday, June 22nd. Three research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $157.52.

Shares of NASDAQ:SRPT opened at $159.25 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 10.88 and a quick ratio of 9.89. The firm has a market capitalization of $10.27 billion, a P/E ratio of -96.77 and a beta of 1.30. Sarepta Therapeutics has a 12-month low of $42.97 and a 12-month high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.99). The company had revenue of $73.53 million during the quarter, compared to the consensus estimate of $71.53 million. Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The firm’s quarterly revenue was up 110.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.48) EPS. equities research analysts predict that Sarepta Therapeutics will post -3.67 earnings per share for the current year.

In other Sarepta Therapeutics news, SVP David T. Howton sold 50,000 shares of the business’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $136.46, for a total transaction of $6,823,000.00. Following the completion of the sale, the senior vice president now owns 37,967 shares in the company, valued at $5,180,976.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram bought 16,000 shares of the stock in a transaction on Wednesday, August 15th. The shares were acquired at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the purchase, the chief executive officer now owns 399,250 shares of the company’s stock, valued at $50,010,055. The disclosure for this purchase can be found here. 7.90% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in SRPT. SG Americas Securities LLC increased its stake in Sarepta Therapeutics by 80.2% during the first quarter. SG Americas Securities LLC now owns 4,386 shares of the biotechnology company’s stock valued at $325,000 after purchasing an additional 1,952 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of Sarepta Therapeutics by 831.1% during the first quarter. Prudential Financial Inc. now owns 53,215 shares of the biotechnology company’s stock valued at $3,942,000 after acquiring an additional 47,500 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 10.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 320,456 shares of the biotechnology company’s stock valued at $23,743,000 after acquiring an additional 31,107 shares during the period. Neuberger Berman Group LLC boosted its holdings in shares of Sarepta Therapeutics by 41.6% during the first quarter. Neuberger Berman Group LLC now owns 25,178 shares of the biotechnology company’s stock valued at $1,865,000 after acquiring an additional 7,403 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 127.4% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 10,551 shares of the biotechnology company’s stock valued at $782,000 after acquiring an additional 5,912 shares during the period. Hedge funds and other institutional investors own 89.99% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Further Reading: Should You Consider an Index Fund?

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.